Modulating immune responses and inflammation

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 2, 2010, Pages 219-222

  Leder, Christoph ^a   Ziegler, Melanie ^a   Gawaz, Meinrad ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Immune modulation; Immune response; Inflammation; Myocarditis

Indexed keywords

ADALIMUMAB; ETANERCEPT; FINGOLIMOD; GAMMA INTERFERON; IMATINIB; METHOTREXATE; NATALIZUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DRUG INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; IMMUNOMODULATION; INFLAMMATION; MULTIPLE SCLEROSIS; MYOCARDITIS; NATURAL KILLER CELL; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE;

AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; HUMANS; IMMUNE SYSTEM PROCESSES; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; MYOCARDITIS;

EID: 77951523498     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1251507     Document Type: Short Survey

References (28)

1. Ley K, Laudanna C, Cybulsky M I., Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007 7 (9) 678-689 (Pubitemid 47327397)
2. Eming S A., Krieg T, Davidson J M. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol 2007 127 (3) 514-525 (Pubitemid 46271017)
3. Branton M H., Kopp J B. TGF-beta and fibrosis. Microbes Infect 1999 1 (15) 1349-1365
4. Khatami M. Inflammation, aging, and cancer: tumoricidal versus tumorigenesis of immunity: a common denominator mapping chronic diseases. Cell Biochem Biophys 2009 55 (2) 55-79
5. Aktas O, Kieseier B, Hartung H P. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci 2010 January 4 (Epub ahead of print)
6. Schett G. Bone formation versus bone resorption in ankylosing spondylitis. Adv Exp Med Biol 2009 649 114-121
7. Libby P. Inflammation in atherosclerosis. Nature 2002 420 (6917) 868-874 (Pubitemid 36019640)
8. Kühl U, Schultheiss H P. Viral myocarditis: diagnosis, aetiology and management. Drugs 2009 69 (10) 1287-1302
9. Hill S L., Rose N R. The transition from viral to autoimmune myocarditis. Autoimmunity 2001 34 (3) 169-176
10. Feldman A M., McNamara D. Myocarditis. N Engl J Med 2000 343 (19) 1388-1398
11. Santangeli P, Pieroni M. Immunosuppressive and antiviral treatment of inflammatory cardiomyopathy. Recent Pat Cardiovasc Drug Discov 2009 4 88-97
12. Reiser H, Stadecker M J. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 1996 335 (18) 1369-1377 (Pubitemid 26360457)
13. Linsley P S., Ledbetter J A. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993 11 191-212 (Pubitemid 23115006)
14. Krummel M F., Allison J P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995 182 (2) 459-465
15. Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov 2006 5 (3) 185-186 (Pubitemid 43336031)
16. Matloubian M, Lo C G., Cinamon G et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004 427 (6972) 355-360 (Pubitemid 38133663)
17. Menge T, Weber M S., Hemmer B et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 2008 68 (17) 2445-2468
18. Gräler M H., Goetzl E J. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004 18 (3) 551-553
19. Meyer L M., Miller F R., Rowen M J., Bock G, Rutzky J. Treatment of acute leukemia with amethopterin (4-amino, 10-methyl pteroyl glutamic acid). Acta Haematol 1950 4 (3) 157-167
20. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005 4 (6) 510-518 (Pubitemid 40861993)
21. Bain B, Brazil M. Adalimumab. Nat Rev Drug Discov 2003 2 (9) 693-694 (Pubitemid 37361784)
22. Garrison L, McDonnell N D. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 1999 58 (suppl 1) I65-I69
23. Nishimoto N, Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol 2008 (181) 151-160
24. Fabian M A., Biggs W H. III, Treiber D K. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005 23 (3) 329-336
25. Druker B J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002 1 (1) 31-36
26. Deininger M W., Druker B J. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003 55 (3) 401-423 (Pubitemid 37013211)
27. Leder C, Ortler S, Seggewiss R, Einsele H, Wiendl H. Modulation of T-effector function by imatinib at the level of cytokine secretion. Exp Hematol 2007 35 (8) 1266-1271 (Pubitemid 47088775)
28. Koretzky G A., Abtahian F, Silverman M A. SLP76 and SLP65: complex regulation of signalling in lymphocytes and beyond. Nat Rev Immunol 2006 6 (1) 67-78 (Pubitemid 43279754)